Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8949604 | 0.80 | HSD17B10 (0.42) | TSHRKDM4EHCAR3ALDH1A1POLB | |
| SCHEMBL2036709 | 0.77 | TSHR (0.62) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL16378794 | 0.73 | TSHR (0.45) | TSHRCYP3A4KDM4EGAAALDH1A1 | |
| SCHEMBL4554976 | 0.73 | TSHR (0.60) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL7328486 | 0.72 | TSHR (0.55) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL7041286 | 0.71 | TSHR (0.53) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL18676266 | 0.71 | ALDH1A1 (0.55) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL29740661 | 0.70 | TSHR (0.56) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL11880900 | 0.70 | TSHR (0.51) | TSHRCYP3A4KDM4EGAAHCAR3 | |
| SCHEMBL9769601 | 0.70 | ALDH1A1 (0.54) | TSHRCYP3A4KDM4EGAAHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504637-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160106648-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-9248086-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150174026-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140326269-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8758451-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140013520-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8444715-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120272990-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8187340-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110154583-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120272990-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TSHR 4752/4885CYP3A4 1216/4885KDM4E 2691/4885 |
| US-20110154583-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TSHR 4752/4885CYP3A4 1216/4885KDM4E 2691/4885 |
| US-20160106648-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TSHR 4752/4885CYP3A4 1216/4885KDM4E 2691/4885 |
| US-20140013520-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TSHR 4752/4885CYP3A4 1216/4885KDM4E 2691/4885 |
| US-20150174026-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TSHR 4752/4885CYP3A4 1216/4885KDM4E 2691/4885 |
| US-20140326269-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TSHR 4752/4885CYP3A4 1216/4885KDM4E 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.